Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Relmada Therapeutics

NASDAQ RLMD
$1.81 0.15 9.04%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
8.21M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
7.06M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.42
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
30.41M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
248.08 %

Upcoming events Relmada Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Relmada Therapeutics

Stock analysis Relmada Therapeutics

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.11 -1.50
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
0.44 1.38
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.10 -0.54
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.02 0.35
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-337.38 -27.86

Price change Relmada Therapeutics per year

0.25$ 3.64$
Min Max

Summary analysis Relmada Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Relmada Therapeutics

Revenue and net income Relmada Therapeutics

All parameters

About company Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead program is REL-1017, is a new chemical entity and novel N-methyl-D-aspartate receptor channel blocker for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is based in Coral Gables, Florida.
Address:
2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Company name: Relmada Therapeutics
Issuer ticker: RLMD
ISIN: US75955J4022
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-10-09
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.relmada.com